<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433065</url>
  </required_header>
  <id_info>
    <org_study_id>MDT20009TMV003</org_study_id>
    <nct_id>NCT04433065</nct_id>
  </id_info>
  <brief_title>TTVR Early Feasibility Study</brief_title>
  <official_title>The Early Feasibility Study of the Transcatheter Tricuspid Valve Replacement System Transfemoral System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this early feasibility study is to gain early clinical insight into the&#xD;
      performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended&#xD;
      for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid&#xD;
      valve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, prospective, non-randomized, investigational, and pre-market.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of implant or delivery related serious adverse events</measure>
    <time_frame>Through 30 days post-procedure</time_frame>
    <description>Rate of implant or delivery related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful access, delivery of implant, and retrieval of the delivery system assessed by definitions per Mitral Valve Academic Research Consortium (MVARC)</measure>
    <time_frame>During Procedure</time_frame>
    <description>For procedural success to be present, device success must have been achieved without major clinical complications as detailed per clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement (part 2: endpoint definitions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TR Grade from baseline</measure>
    <time_frame>Through 30 days post-procedure</time_frame>
    <description>Change in TR Grade from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no significant TV stenosis</measure>
    <time_frame>Through 30 days post-procedure</time_frame>
    <description>Rate of no significant TV stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA Class from baseline</measure>
    <time_frame>Through 30 days post-procedure</time_frame>
    <description>Change in NYHA Class from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Primary Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Intrepid TTVR System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrepid™ TTVR System</intervention_name>
    <description>Device: Intrepid™ TTVR System</description>
    <arm_group_label>Primary Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Heart Team agrees that patient is deemed symptomatic despite medical therapy&#xD;
             (including obligatory diuretic) and a candidate for bioprosthetic tricuspid valve&#xD;
             replacement&#xD;
&#xD;
          -  Subject is at an intermediate or greater estimated risk of mortality with tricuspid&#xD;
             valve surgery as determined by the local Heart Team&#xD;
&#xD;
          -  Subjects with severe symptomatic primary and / or secondary tricuspid regurgitation&#xD;
             determined by the Echocardiography Core Lab assessment of a qualifying transthoracic&#xD;
             echocardiogram (TTE) and transesophageal echocardiogram (TEE)&#xD;
&#xD;
          -  New York Heart Association (NYHA) Function Class II or greater&#xD;
&#xD;
          -  Subject anatomically suitable for the Intrepid TTVR delivery system including&#xD;
             transfemoral access&#xD;
&#xD;
          -  Subject and the treating physician agree that the subject will return for all required&#xD;
             post-procedure follow-up visits&#xD;
&#xD;
          -  Subject meets the legal minimum age to provide informed consent based on local&#xD;
             regulatory requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated life expectancy of less than 24 months due to associated non-cardiac&#xD;
             co-morbid conditions&#xD;
&#xD;
          -  Anatomic contraindications for Intrepid™ TTVR (e.g., annular dimensions)&#xD;
&#xD;
          -  Evidence of intracardiac mass, inferior vena cava, or femoral venous mass or thrombus&#xD;
&#xD;
          -  Implanted with venous stents (iliac and/or femoral) or inferior vena cava (IVC) filter&#xD;
             or congenital abnormalities of the IVC that would preclude ability for transfemoral&#xD;
             access of delivery system&#xD;
&#xD;
          -  Echocardiographic evidence of severe right ventricular dysfunction&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;30 as measured by resting echocardiogram&#xD;
             within 30 days of the Index Procedure&#xD;
&#xD;
          -  Need for emergent or urgent surgery&#xD;
&#xD;
          -  Untreated clinically significant coronary artery disease requiring revascularization&#xD;
&#xD;
          -  Carcinoid tricuspid regurgitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Brown</last_name>
    <phone>763-514-4000</phone>
    <email>rs.tmvrtransfemoralefs@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynnett Stahl</last_name>
    <email>rs.tmvrtransfemoralefs@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB) Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mustafa Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abrazo Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Spies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Oakley</last_name>
    </contact>
    <investigator>
      <last_name>Stanley Chetcuti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Sorajja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susheel Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Yakubov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Firas Zahr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle Harrisburg Campus</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hemal Gada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sachin Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora St. Lukes Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Kresa</last_name>
    </contact>
    <investigator>
      <last_name>Tanvir Bajwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

